The long‐term health, social, and financial burden of hypoxic–ischaemic encephalopathy
-
- Paul Eunson
- Department of Paediatric Neurosciences Royal Hospital for Sick Children Edinburgh UK
説明
<jats:p>Infants who suffer hypoxic–ischaemic encephalopathy (<jats:styled-content style="fixed-case">HIE</jats:styled-content>) at term are at risk of dying or developing severe cerebral palsy (<jats:styled-content style="fixed-case">CP</jats:styled-content>). Children with severe <jats:styled-content style="fixed-case">CP</jats:styled-content> often have other neurodevelopmental disabilities, which may affect their quality of life as much as the <jats:styled-content style="fixed-case">CP</jats:styled-content> itself. New treatments for <jats:styled-content style="fixed-case">HIE</jats:styled-content>, such as cooling, may improve motor outcomes, but affected infants may still have significant cognitive or communication problems. Infants who have experienced <jats:styled-content style="fixed-case">HIE</jats:styled-content> and develop <jats:styled-content style="fixed-case">CP</jats:styled-content> will require significant medical input throughout childhood and adult life. The costs of this medical input are high, but the indirect costs to the child, his or her family, and the relevant social services and education systems are many times greater. When demonstrating the cost‐effectiveness of interventions aimed at preventing or treating <jats:styled-content style="fixed-case">HIE</jats:styled-content>, these additional costs should be taken into account.</jats:p>
収録刊行物
-
- Developmental Medicine & Child Neurology
-
Developmental Medicine & Child Neurology 57 (S3), 48-50, 2015-03-19
Wiley